Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1975 | Intermediate dose thromboprophylaxis Wiki | 1.00 |
| drug846 | Capillary and salivary sampling Wiki | 1.00 |
| drug3902 | Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki | 0.71 |
Navigate: Correlations HPO
There is one clinical trial.
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be randomized to standard prophylactic dose LMWH (standard of care arm) or intermediate-dose LMWH (intervention arm).
Description: Risk of all-cause mortality
Measure: Mortality Time: 30 Days post interventionDescription: Risk of ISTH defined major bleeding
Measure: Major Bleeding Time: 30 Days post interventionDescription: Risk of ischemic stroke, myocardial infarction and/or limb ischemia
Measure: Arterial Thrombosis Time: 30 Days post interventionDescription: Risk of symptomatic venous thromboembolism
Measure: Venous Thromboembolism Time: 30 Days post interventionDescription: duration of intensive care measures
Measure: ICU admission, intubation/ventilation Time: 30 Days post interventionDescription: The number of units of packed red blood cells transfused
Measure: Packed Red Blood Cell Transfusions Time: 30 Days post interventionDescription: The number of units of platelets transfused
Measure: Platelet Transfusions Time: 30 Days post interventionDescription: The number of units of Fresh Frozen Plasma Transfused
Measure: Fresh Frozen Plasma Transfusions Time: 30 Days post interventionDescription: The number of units of Cryoprecipitate Transfused
Measure: Cryoprecipitate Transfusions Time: 30 Days post interventionDescription: The number of units of Prothrombin Complex ConcentrateTransfused
Measure: Prothrombin Complex Concentrate Transfusions Time: 30 Days post interventionDescription: Will be performed in stored plasma using Calibrated Automated Thrombogram. The endogenous thrombin potential will be calculated in units of nM.Min.
Measure: The endogenous thrombin potential will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: These assays will be performed in stored plasma. Quantification of cfDNA will be performed using Qubit dsDNA HS Assay kit. Histones H4, citrullinated-histone and DNA-myeloperoxidase will be measured using commercially available ELISA kit.
Measure: Plasma levels of cell-free DNA will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: will be measured in stored plasma using a commercially available ELISA kit.
Measure: PAI-1 Time: 30 days post interventionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports